Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of TLL-018 in active rheumatoid arthritis
CTR20244903Phase 3Active
- Sponsor
- Highlight Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib in rheumatoid arthritis (RA), sponsored by Highlight Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20244903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244903.